Cardiac myosin-binding protein C mutations and hypertrophic cardiomyopathy: haploinsufficiency, deranged phosphorylation, and cardiomyocyte dysfunction
- PMID: 19273718
- DOI: 10.1161/CIRCULATIONAHA.108.838672
Cardiac myosin-binding protein C mutations and hypertrophic cardiomyopathy: haploinsufficiency, deranged phosphorylation, and cardiomyocyte dysfunction
Abstract
Background: Mutations in the MYBPC3 gene, encoding cardiac myosin-binding protein C (cMyBP-C), are a frequent cause of familial hypertrophic cardiomyopathy. In the present study, we investigated whether protein composition and function of the sarcomere are altered in a homogeneous familial hypertrophic cardiomyopathy patient group with frameshift mutations in MYBPC3 (MYBPC3(mut)).
Methods and results: Comparisons were made between cardiac samples from MYBPC3 mutant carriers (c.2373dupG, n=7; c.2864_2865delCT, n=4) and nonfailing donors (n=13). Western blots with the use of antibodies directed against cMyBP-C did not reveal truncated cMyBP-C in MYBPC3(mut). Protein expression of cMyBP-C was significantly reduced in MYBPC3(mut) by 33+/-5%. Cardiac MyBP-C phosphorylation in MYBPC3(mut) samples was similar to the values in donor samples, whereas the phosphorylation status of cardiac troponin I was reduced by 84+/-5%, indicating divergent phosphorylation of the 2 main contractile target proteins of the beta-adrenergic pathway. Force measurements in mechanically isolated Triton-permeabilized cardiomyocytes demonstrated a decrease in maximal force per cross-sectional area of the myocytes in MYBPC3(mut) (20.2+/-2.7 kN/m(2)) compared with donor (34.5+/-1.1 kN/m(2)). Moreover, Ca(2+) sensitivity was higher in MYBPC3(mut) (pCa(50)=5.62+/-0.04) than in donor (pCa(50)=5.54+/-0.02), consistent with reduced cardiac troponin I phosphorylation. Treatment with exogenous protein kinase A, to mimic beta-adrenergic stimulation, did not correct reduced maximal force but abolished the initial difference in Ca(2+) sensitivity between MYBPC3(mut) (pCa(50)=5.46+/-0.03) and donor (pCa(50)=5.48+/-0.02).
Conclusions: Frameshift MYBPC3 mutations cause haploinsufficiency, deranged phosphorylation of contractile proteins, and reduced maximal force-generating capacity of cardiomyocytes. The enhanced Ca(2+) sensitivity in MYBPC3(mut) is due to hypophosphorylation of troponin I secondary to mutation-induced dysfunction.
Similar articles
-
The mechanics of the heart: zooming in on hypertrophic cardiomyopathy and cMyBP-C.FEBS Lett. 2022 Mar;596(6):703-746. doi: 10.1002/1873-3468.14301. Epub 2022 Feb 28. FEBS Lett. 2022. PMID: 35224729 Review.
-
Haploinsufficiency of MYBPC3 exacerbates the development of hypertrophic cardiomyopathy in heterozygous mice.J Mol Cell Cardiol. 2015 Feb;79:234-43. doi: 10.1016/j.yjmcc.2014.11.018. Epub 2014 Nov 25. J Mol Cell Cardiol. 2015. PMID: 25463273 Free PMC article.
-
Familial hypertrophic cardiomyopathy: functional effects of myosin mutation R723G in cardiomyocytes.J Mol Cell Cardiol. 2013 Apr;57:13-22. doi: 10.1016/j.yjmcc.2013.01.001. Epub 2013 Jan 11. J Mol Cell Cardiol. 2013. PMID: 23318932
-
Contractile dysfunction irrespective of the mutant protein in human hypertrophic cardiomyopathy with normal systolic function.Circ Heart Fail. 2012 Jan;5(1):36-46. doi: 10.1161/CIRCHEARTFAILURE.111.963702. Epub 2011 Dec 16. Circ Heart Fail. 2012. PMID: 22178992
-
Cardiac myosin binding protein C phosphorylation in cardiac disease.J Muscle Res Cell Motil. 2012 May;33(1):43-52. doi: 10.1007/s10974-011-9280-7. Epub 2011 Nov 30. J Muscle Res Cell Motil. 2012. PMID: 22127559 Free PMC article. Review.
Cited by
-
Generation of induced pluripotent stem cells from an individual with early onset and severe hypertrophic cardiomyopathy linked to MYBPC3: c.772G > A mutation.Hum Cell. 2024 Jul;37(4):1205-1214. doi: 10.1007/s13577-024-01073-y. Epub 2024 May 18. Hum Cell. 2024. PMID: 38762696 Free PMC article.
-
MYBPC3-c.772G>A mutation results in haploinsufficiency and altered myosin cycling kinetics in a patient induced stem cell derived cardiomyocyte model of hypertrophic cardiomyopathy.J Mol Cell Cardiol. 2024 Jun;191:27-39. doi: 10.1016/j.yjmcc.2024.04.010. Epub 2024 Apr 20. J Mol Cell Cardiol. 2024. PMID: 38648963
-
Hypertrophic cardiomyopathy in MYBPC3 carriers in aging.J Cardiovasc Aging. 2024 Jan;4(1):9. doi: 10.20517/jca.2023.29. Epub 2024 Jan 11. J Cardiovasc Aging. 2024. PMID: 38406555 Free PMC article.
-
An Update on MYBPC3 Gene Mutation in Hypertrophic Cardiomyopathy.Int J Mol Sci. 2023 Jun 22;24(13):10510. doi: 10.3390/ijms241310510. Int J Mol Sci. 2023. PMID: 37445689 Free PMC article. Review.
-
Circulating Acylcarnitines Associated with Hypertrophic Cardiomyopathy Severity: an Exploratory Cross-Sectional Study in MYBPC3 Founder Variant Carriers.J Cardiovasc Transl Res. 2023 Dec;16(6):1267-1275. doi: 10.1007/s12265-023-10398-2. Epub 2023 Jun 6. J Cardiovasc Transl Res. 2023. PMID: 37278928 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous